Pathophysiology of Diabetic Dyslipidemia
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
Accumulating clinical evidence has suggested serum triglyceride (TG) is a leading predictor of atherosclerotic cardiovascular disease, comparable to low-density lipoprotein (LDL)-cholesterol (C) in populations with type 2 diabetes, which exceeds the predictive power of hemoglobinA1c. Atherogenic dyslipidemia in diabetes consists of elevated serum concentrations of TG-rich lipoproteins (TRLs), a high prevalence of small dense low-density lipoprotein (LDL), and low concentrations of cholesterol-rich high-density lipoprotein (HDL)2-C. A central lipoprotein abnormality is an increase in large TG-rich very-low-density lipoprotein (VLDL)1, and other lipoprotein abnormalities are metabolically linked to increased TRLs. Insulin critically regulates serum VLDL concentrations by suppressing hepatic VLDL production and stimulating VLDL removal by activation of lipoprotein lipase. It is still debated whether hyperinsulinemia compensatory for insulin resistance is causally associated with the overproduction of VLDL. This review introduces experimental and clinical observations revealing that insulin resistance, but not hyperinsulinemia stimulates hepatic VLDL production. LDL and HDL consist of heterogeneous particles with different size and density. Cholesterol-depleted small dense LDL and cholesterol-rich HDL2 subspecies are particularly affected by insulin resistance and can be named "Metabolic LDL and HDL," respectively. We established the direct assays for quantifying small dense LDL-C and small dense HDL(HDL3)-C, respectively. Subtracting HDL3-C from HDL-C gives HDL2-C. I will explain clinical relevance of measurements of LDL and HDL subspecies determined by our assays. Diabetic kidney disease (DKD) substantially worsens plasma lipid profile thereby potentiated atherogenic risk. Finally, I briefly overview pathophysiology of dyslipidemia associated with DKD, which has not been so much taken up by other review articles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, the activation of PPARα reduces small dense LDL particles by (1) producing apo C-III-poor VLDL particles that interacts less well CETP and (2) increasing the formation of large buoyant LDL that has a high affinity to and are easily taken up by LDL receptor.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-elevated LDL cholesterol values together with higher triglycerides and lower HDL-cholesterol are common in patients with abdominal obesity, T2D, and metabolic syndrome (61, 62); these individuals often still have elevated atherogenic lipoproteins such as non-HDL (63), small LDL particles (62, 64), and VLDL (62, 64).”
From Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial (2019) · cites this paper as [64]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cholesterol accumulation in the brain, particularly in astrocytes, contributes to this pathological process.”
From Cholesterol-driven pathological astrocytic responses in diabetes-associated cognitive impairment through astrocytic SCAP accumulation and NF-κB–C3 signaling modulation (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411
Lewis, G. F., Carpentier, A., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,333
Stampfer, M. J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110036029 · Cited by 1,079
Cited by
Items 201–300 of 552
Mohyeldin, S. M., Talaat, W., Kamal, M. F., Daabees, H. G., El‐Tahawy, M. M. T., & Keshk, R. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-53203-z · Cited by 8
Kumar, S., Prakash, P., Kumari, R., & Kumar, N. (2024) · Cureus · doi:10.7759/cureus.52709 · Cited by 7
“FFA and triglycerides derived from FFA or FFA inhibit apolipoprotein B (apoB) degradation in the liver, thereby stimulating the overproduction of VLDL1 and is metabolically associated with a preponderance of small dense LDL and reduced large cholesterol-rich HDL2 [12].”
BackgroundZhong, L., Yang, X., Shang, Y., Yao, Y., Li, J., Liu, S., Zhang, Y., Liu, J., & Jiang, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1405726 · Cited by 7
“Overproduction of large triglyceride-rich lipoproteins and impairment of catabolism are associated with insulin resistance, which contributes to hypertriglyceridemia frequently seen in patients with DM (54).”
Alshahrani, M. Y., Amri, F. S. A., Alzahrani, M. A., Alshahrani, A., Kader, D. H. A., Almasabi, F., Zafrah, H. A., Dallak, M. A., Osman, O. M., Al‐Ani, B., et al. (2024) · Ultrastructural Pathology · doi:10.1080/01913123.2024.2440479 · Cited by 7
“8,9 CD86 is expressed on macrophages (M1 marker) and other antigen-presenting cells involved in T-cell activation and survival that trigger severe inflammation and tissue damage in patients with systemic sclerosis that is characterized by dysregulation of the immune system.”
Impact of SGLT2 Inhibitors on Lipoproteins in Type 2 Diabetes
Corral, P., Nardelli, N., Elbert, A. E., Aranguren, F., & Schreier, L. E. (2025) · Current Diabetes Reports · doi:10.1007/s11892-024-01572-0 · Cited by 9
“Hyperinsulinemia compensatory for insulin resistance is causally associated with the overproduction of TG by promoting glycolysis, increasing the glycerol pool as well as the flux of free fatty acids into the liver and activating de novo lipogenesis, both necessary for the synthesis of TG [24].”
Gao, Y. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01880-w · Cited by 7
“In states of insulin resistance, an elevated availability of free fatty acids (FFAs) drives liver release of very low-density lipoprotein (VLDL) while simultaneously inhibiting the degradation of apolipoprotein B [40].”
Potential role of polydatin in treating diabetes mellitus and diabetes-related chronic complications
Yasmin, F., & Tang, K. S. (2025) · Bioscience Reports · doi:10.1042/bsr20241307 · Cited by 8
“Dyslipidaemia is a prevalent condition among patients with type 2 diabetes, typically characterized by elevated levels of triglycerides and low-density lipoprotein cholesterol (LDL-C), along with decreased levels of high-density lipoprotein cholesterol (HDL-C) [38].”
Kim, J. Y., Kim, N. H., Lee, J. Y., Kim, D., & Kim, S. G. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf053 · Cited by 10
Sheng, L., Cao, Z., Wang, L., Xu, Y., & Gui, D. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1631312 · Cited by 8
“LDL size is negatively regulated by serum TG levels, and LDL size is signi fi cantly reduced in hypertriglyceridemic subjects (42).”
Niu, T., Wang, S., Zhang, H., Zhu, W., Liu, K., Zhou, X., Sun, R., Niu, D., & Yuan, Y. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01534-w · Cited by 7
Zhang, W., Jin, J., Zhang, H., Zhu, Y., Dong, Q., Sun, J., Guo, Y., Dou, K., Xu, R., & Li, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1041555 · Cited by 7
“Cardiovascular disease (CVD) is one of major causes of death in the world with atherosclerotic cardiovascular disease (ASCVD) accounting for half of these deaths.”
BackgroundInfluentialWu, T., Chou, C., Cheng, C.-F., Lu, S.-X., Wu, Y., & Wang, L. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01787-7 · Cited by 7
“The fasting blood levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (FTG), and glucose (FPG) were determined by an autoanalyzer (Toshiba TBA c16000; Toshiba Medical System, Holliston, MA, USA) with commercial kits (Denka Seiken, Tokyo,…”
BackgroundInfluentialNaderian, S., Nikniaz, Z., Farhangi, M. A., Nikniaz, L., Samad‐Soltani, T., & Rostami, P. (2024) · BMC Public Health · doi:10.1186/s12889-024-19261-8 · Cited by 9
“Hirano T et al. also demonstrated that serum triglyceride would be main predictor of atherosclerotic cardiovascular disorder in type 2 diabetes [74].”
BackgroundZhou, J., & Park, S. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030207 · Cited by 7
“T2DM causes dyslipidemia because lipoprotein lipase activity is reduced due to reduced insulin activity [5].”
BackgroundBoutari, C., Rizos, C. V., Doumas, M. N., Liamis, G. L., Skoumas, I., Rallidis, L. S., Garoufi, A., Kolovou, G. D., Τζιόμαλος, Κ., Skalidis, E. I., et al. (2022) · Pharmaceuticals · doi:10.3390/ph16010044 · Cited by 10
“Atherogenic dyslipidemia in diabetes consists of elevated serum concentrations of triglyceride-rich lipoproteins (TRLs), a high prevalence of small dense LDL, and low concentrations of cholesterol-rich high-density lipoprotein (HDL)-C [8].”
BackgroundAl‐Sowayan, N. S., & AL-Sallali, R. M. (2023) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2023.102589 · Cited by 7
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk
Nysather, J. A., Kaya, E., Manka, P. P., Gudsoorkar, P. S., & Syn, W. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2023.04.001 · Cited by 8
Klobučar, I., Habisch, H., Klobučar, L., Trbušić, M., Pregartner, G., Berghold, A., Kostner, G. M., Scharnagl, H., Madl, T., Frank, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25095050 · Cited by 9
“An accelerated catabolism of the small dense HDL generated by the CETP-mediated TG-enrichment of HDL and the subsequent HL-mediated HDL lipolysis are the major causes for decreased levels of HDL in MS (reviewed in [6,7]).”
BackgroundTani, S., Yagi, T., Matsuo, R., Kawauchi, K., Atsumi, W., Matsumoto, N., & Okumura, Y. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.06.006 · Cited by 8
Soares, A. L. D. S., Brech, G. C., Machado‐Lima, A., dos Santos, J. R., Greve, J. M. D., Grecco, M. V., Afonso, M. S., Sousa, J. C., Rodrigues, A. T., Lino, M. H. D. S., et al. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22020184 · Cited by 7
“As insulin resistance decreases, so does the production of VLDL in the liver, resulting in lower levels of LDL and triglycerides in the bloodstream [42].”
Jang, W. B., Rethineswaran, V. K., & Kwon, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104603 · Cited by 9
“The most prominent clinical expression of this association is diabetic dyslipidemia, which is marked by high levels of TGs in VLDL and low levels of HDL cholesterol [108].”
Zeng, X., Yuan, Y., Li, Y., Hu, Z., & Hu, S. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115304 · Cited by 10
Păduraru, L., Vesa, C. M., Popoviciu, M. S., Ghitea, T. C., & Zaha, D. C. (2025) · Healthcare · doi:10.3390/healthcare13202605 · Cited by 7
“Dyslipidemia in T2DM typically presents as hypertriglyceridemia, reduced high-density lipoprotein cholesterol (HDL-C), and a predominance of small dense low-density lipoprotein (LDL) particles, all of which promote atherogenesis [4].”
Caturano, A., Nilo, D., Lorenzo, G. D., Rocco, M. P., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Moretto, S. M., Acierno, C., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm43143 · Cited by 9
“This requires an integrated approach addressing all modifiable risk factors [225,228].”
Yu, B., Hu, X., Liu, J., Nie, Z., Bu, C. R. L., Li, G., Zhou, Y., & Dong, H. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s423458 · Cited by 7
Cutruzzolà, A., Parise, M., Scavelli, F. B., Fiorentino, R., Luca, S. D., Molfetta, S. D., Gnasso, A., & Irace, C. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.06.013 · Cited by 6
Gong, S., Jin, J., Mao, J., Li, H., Mo, Y., Zhou, Q., & Gan, S. (2024) · Medicine · doi:10.1097/md.0000000000039792 · Cited by 6
“[41,42] This leads to a shift from anti-atherogenic to pro-atherogenic. sdLDL is a subcomponent of LDL with smaller particles and higher density.”
BackgroundUllah, H., Jan, T., Ahmad, B., Nawaz, T., Khan, I., Ahmad, K., Rehman, A. U., Murshed, A., Lu, J., Ali, A., et al. (2024) · Journal of Food Quality · doi:10.1155/2024/7096736 · Cited by 8
Kidney Adaptations Prevent Loss of Trace Elements in Wistar Rats with Early Metabolic Syndrome
Sánchez‐Solís, C. N., Hernández-Fragoso, H., Aburto-Luna, V., Barbier, O. C., Díaz, A., Brambila, E., & Treviño, S. (2020) · Biological Trace Element Research · doi:10.1007/s12011-020-02317-2 · Cited by 6
“These changes are promoted by chronic hyperglycemia and nonenzymatic glycosylation of non-glycosylated substances to produce advanced glycosylation end-products (AGEs) [63, 64] and hypertriglyceridemia, which reduce fibrinolytic activity, resulting in vascular embolization of glomerular capillaries [65, 66] and favor…”
BackgroundWidhiantara, G., Permatasari, A. A. A. P., & Wiradana, P. A. (2021) · PLANT ARCHIVES · doi:10.51470/plantarchives.2021.v21.no1.049 · Cited by 6
“The most common clinical features of this disease are increased levels of total cholesterol (Nelson, 2013), triglycerides (Chandalia and Abate, 2004), and LDL (Low Density Lipoprotein) (Hirano, 2018), and decreased HDL (High Density Lipoprotein) (Forrester, Makkar and Shah, 2005).”
BackgroundAl-Samawi, R. I., & Smaism, M. F. (2021) · Indian Heart Journal · doi:10.1016/j.ihj.2021.12.005 · Cited by 6
Chiu, T. H. T., Kao, Y.-C., Wang, L.-Y., Chang, H.-R., & Lin, C. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.807810 · Cited by 8
“Detailed examination of subtypes of lipoproteins, such as very-low-density lipoprotein (VLDL) and chylomicron particles, and different sizes of LDL-p and high-density lipoprotein particles (HDLp), may also yield insight on the risk of diabetes (3, 9).”
BackgroundPrognostic Implication of Small Dense LDL-Cholesterol Levels following Acute Coronary Syndrome
Imamura, T., Hori, M., Narang, N., Ueno, H., & Kinugawa, K. (2023) · Medicina · doi:10.3390/medicina59010158 · Cited by 9
“Association between small dense LDL cholesterol and comorbidities, such as metabolic syndrome and insulin resistance, remains a future concern [4].”
BackgroundChoi, W., Kang, J., Park, J. Y., Hong, A. R., Yoon, J. H., Kim, H. K., & Kang, H. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152274 · Cited by 8
Xu, L., Chen, X., Lu, J., Xu, Y., Yang, H., Zhou, X., Zhou, J., Xu, J., & Shen, H. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00667-y · Cited by 8
“CVs were di ned as (1) death caused by cardiovascular disease, (2) onset of acute coronary syndrome, (3) congestive heart failure, (4) need for coronary or other arterial revascularization, (5) stroke and registered in Table 1.”
BackgroundMethodWu, L., Zhou, N., Sun, J.-Y., Yu, H., & Wang, R. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001270 · Cited by 6
Rech, G., da Silva, L. L., da Silva, K., Silva, T. M., Fontana, R. C., Salvador, M. M., Jahn, M. P., & Camassola, M. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13247 · Cited by 8
Sex differences in circulating metabolites across glycemic status and risk of coronary heart diseasePreprint
Yoshida, Y., Li, D., Li, X., Fonseca, V. A., Qi, L., & Mauvais‐Jarvis, F. (2024) · medRxiv · doi:10.1101/2024.07.23.24310540 · Cited by 10
Zhang, Y., Chen, B., & Wan, Q. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1571602 · Cited by 6
“In the state of insulin resistance, ApoB degradation is inhibited, leading to an overproduction of very low-density lipoproteins (VLDL), which results in the predominance of sdLDL due to increased activity of cholesteryl ester transfer protein and hepatic lipases (37, 38).”
Aida, H., Tanaka, M., Sato, T., Kawaharata, W., Matsumori, R., Hosaka, I., Akiyama, Y., Nakata, K., Kouzu, H., Hanawa, N., et al. (2025) · Hypertension Research · doi:10.1038/s41440-025-02374-x · Cited by 7
“Small dense low-density lipoprotein cholesterol (sdLDL-C) is a subfraction of low-density lipoprotein cholesterol (LDL-C) and typically consists of about 20 – 30% of total LDL-C fractions [8 – 10].”
Selim, S., Alam, M. S., Talukder, S. K., Kabir, M. L., Gaffar, M. A. J., Kabir, M. A., Zarin, N., Rahman, S. I., Nabi, M. M. U., Mustari, M., et al. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01522-z · Cited by 5
Use of lipid ratios to predict vascular target organ damage in youth
Henson, S. E., & Urbina, E. M. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.02.002 · Cited by 5
Effects of High-Fiber Biscuits on Lipid and Anthropometric Profile of Patients with Type 2 Diabetes
Fatmah, F. (2020) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.66.s391 · Cited by 5
In Vitro and In Vivo Antiglycation Effects of Connarus ruber Extract
Takenokuchi, M., Matsumoto, K., Nitta, Y., Takasugi, R., Inoue, Y., Iwai, M., Kadoyama, K., Yoshida, K., Takano‐Ohmuro, H., & Taniguchi, T. (2021) · Planta Medica · doi:10.1055/a-1690-3528 · Cited by 6
“These changes were similar to those previously observed [18,19] and those seen in early-stage human diabetic patients [20], indicating the successful diabetogenic action of STZ.”
ResultNeto, J. C. G. L., Silva, T. L., da Silva, I. G., Félix, N. D. D. C., Maranhão, T. A., & Damasceno, M. M. C. (2022) · Revista de Pesquisa Cuidado é Fundamental Online · doi:10.9789/2175-5361.rpcfo.v14.11014 · Cited by 5
Ahmed, G. O., Rahimi, Z., Kohsari, M., & Shakiba, E. (2023) · Health Science Reports · doi:10.1002/hsr2.1031 · Cited by 5
“A Japanese cohort study on T2DM patients illustrated serum triglycerides (TG) as a much more influential factor than the A1C hemoglobin for predicting CVD in DM patients, even in those with a higher level of blood glucose.(6) Furthermore, dyslipidemia is associated with oxidative stress.”
BackgroundInfluentialLaupsa‐Borge, J., Grytten, E., Bohov, P., Bjørndal, B., Strand, E., Skorve, J., Nordrehaug, J. E., Berge, R. K., Rostrup, E., Mellgren, G., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1020678 · Cited by 6
Klobučar, I., Klobučar, L., Lechleitner, M., Trbušić, M., Pregartner, G., Berghold, A., Habisch, H., Madl, T., Frank, S., & Degoricija, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310681 · Cited by 6
“High levels of TG-rich VLDL, and consequently increased levels of small dense LDL (sdLDL), generated by the action of hepatic lipase (HL) on TG-rich LDL particles (enriched with TG due to cholesterol ester transfer protein (CETP)-mediated transfer of TGs from TG-rich VLDL) as well as low levels of HDL (due to an incre…”
BackgroundHypoglycemic and hypolipidemic effects of Lippia origanoides Kunth in diabetic rats
Miranda, V. C., Pereira, Y. L. G., da Paz, A. P. S., de Souza, K. R., da Silva, M. C. F., Muto, N. A., Monteiro, P. R., Santos, A. V., Hamoy, M., de Medeiros, M. D. G. F., et al. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4162 · Cited by 6
“Diabetes mellitus and atherosclerosis are linked through several pathological pathways, which has drawn attention to the coexistence of dyslipidemia and diabetes in recent years since diabetic patients are at increased risk of the onset and accelerated development of atherosclerosis (Hirano, 2018).”
BackgroundKhojah, H. M. J., & Ahmed, S. (2019) · Journal of International Medical Research · doi:10.1177/0300060519882563 · Cited by 5
“Insulin resistance was shown to negatively affect the lipid profile, inducing endothelial dysfunction and oxidative stress and driving the formation of atheroma and the development of cardiovascular diseases.(40) In our study, moderate to strong positive correlations were found between both total cholesterol and trigl…”
BackgroundYazdanimoghaddam, F., Ghasemi, M., Teamparvar, H., Soltani, N., Aghaei, M., Rezazadeh, H., & Zadhoush, F. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02211-9 · Cited by 6
“Dyslipidemia is a key component of IR which is characterized by hypertriglyceridemia, increased VLDL and LDL levels, and a shift toward smaller size and less protective of HDL particles (Hirano 2018).”
BackgroundSphingolipidomic profile and HDL subfractions in obese dyslipidemic type 2 diabetic patients
Aslan, İ., Aydın, D., Koca, Y., Yılmaz, Ç., Çeker, T., Öztüzün, A., & Aslan, M. (2023) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2023.106719 · Cited by 5
Tian, Y., Xia, J., Li, L., Yang, L., Xiao, H., Gao, G., Wang, Y., Zhang, C., Bu, T., & Sun, G. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250002 · Cited by 5
Padilla, F., Ruiz-Bernes, L. N., Román-Pintos, L. M., Peraza-Zaldívar, J. A., Sander-Padilla, J. G., Lugo‐Sánchez, L. A., RIOS-BRITO, K. F., Arguedas-Núñez, M. M., FLORES-HUANOSTA, D., & González‐Canudas, J. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00410-y · Cited by 6
Nsiah, P., Acquah, S., Bockarie, A. S., Adjei, G., Aniakwaa-Bonsu, E., & Debrah, O. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1551203 · Cited by 5
“It contributes to increased hepatic VLDL production, reduced lipoprotein lipase activity, and impaired HDL metabolism, all of which elevate levels of non-HDL-C and remnant cholesterol (24).”
InfluentialWang, H., Guan, L., Guan, H., Zhong, J., & Zhong, J. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70699 · Cited by 4
“Dyslipidemia refers to abnormalities of serum lipids (Chang and Wu 2013; Hirano 2018; Ezhilvendhan et al. 2021).”
He, Y., Zhou, J., Wang, J., Huang, S., Li, H., Cao, J., & Ye, J. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.12.17 · Cited by 5
Ansari, T., & Sawane, M. (2024) · Cureus · doi:10.7759/cureus.72227 · Cited by 7
Azeez, T. A., Adio, M., & BAMIDELE, O. T. (2021) · Journal of Diabetes and Endocrine Practice · doi:10.4103/jdep.jdep_48_21 · Cited by 5
“[16] Insulin resistance is the main culprit in the pathophysiology of diabetic dyslipidemia.[17]”
BackgroundZhang, T., Hou, Y., Liu, M., Hou, X., Tang, Y. P., Ren, L., & Song, G. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s438757 · Cited by 4
Influencia de la concentración de triglicéridos en la lipoproteína(a) en función de la dislipidemia
Marco-Benedí, V., Cenarro, A., Laclaustra, M., Calmarza, P., Bea, A. M., Vila, À., Morillas, C., Puzo, J., García, J. D. M., Alamán, A. I. F., et al. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.11.005 · Cited by 7
Tobeiha, M., Amin, N., Shahaboddin, M. E., Tabatabaizadeh, M., & Jafarnejad, S. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01350-4 · Cited by 4
“Fasting hypertriglyceridemia and increased lipemia are common in T2DM patients [57, 58].”
Kutoh, E., Kuto, A. N., Okada, R., Akiyama, M., & Kurihara, R. (2024) · Medicina · doi:10.3390/medicina60060991 · Cited by 4
“Non-HDL-C is frequently increased and considered a better parameter for atherogenic lipid than LDL-C [21].”
BackgroundAbdulghani, M. F., & AL‐Fayyadh, S. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1415916 · Cited by 4
Utilising Self-acupressure to Manage Type 2 Diabetes Mellitus Control Parameters
Sukarja, I. M., Sukawana, I. W., Ningtyas, L. A. W., Juanamasta, I. G., & Aungsuroch, Y. (2024) · The Open Nursing Journal · doi:10.2174/0118744346310777240715115656 · Cited by 7
Klobučar, I., Habisch, H., Klobučar, L., Trbušić, M., Pregartner, G., Berghold, A., Kostner, G. M., Scharnagl, H., Madl, T., Frank, S., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12091972 · Cited by 4
“MS dyslipidemia is a consequence of an oversupply of the liver with free fatty acids released from inflamed, insulin-resistant visceral adipose tissue and, in consequence, increased production of TG-enriched VLDL, LDL, and HDL [11,12].”
BackgroundAbu‐Samak, M., Hasoun, L., Barham, A., Mohammad, B. A., Mosleh, I. M., Aljaberi, A., & Awwad, S. H. (2021) · Pharmacia · doi:10.3897/pharmacia.68.e64422 · Cited by 4
Lu, C., Liu, W., Huang, H., Ge, X., Hua, L.-Y., Wang, X., & Su, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.903336 · Cited by 4
“Lowdensity lipoprotein cholesterol (LDL-C) is a heterogeneous group of lipoproteins, among which with smaller sizes and heavier densities were known as small and density LDL-C (sdLDL-C) (8).”
BackgroundTen-year Time-trend Analysis of Dyslipidemia Among Adults in Wuhan
Zhang, M., Wan, Z., Lv, Y., Huang, Y., Liu, H., Xu, H., & Lei, X. (2022) · Current Medical Science · doi:10.1007/s11596-022-2630-4 · Cited by 6
AL‐Saffar, A. M., Al‐Qattan, N. Y., & Al-Sughayer, M. (2023) · Food Science & Nutrition · doi:10.1002/fsn3.3672 · Cited by 3
“Excess consumption of atherogenic SFAs under DM conditions can accelerate the atherosclerotic process and is thought to be harmful (Hirano, 2018).”
BackgroundHirai, H., Higa, M., Morimoto, T., Sakuma, M., Arasaki, O., Nomiyama, T., Node, K., Ueda, S., & Shimabukuro, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010093 · Cited by 5
“In T2DM, possible candidates for residual risks include sdLDL [12], postprandial hypertriglyceridemia [25], and TG-rich lipoproteins [21,25,26].”
BackgroundInfluentialCai, T., Gao, Y., Zhang, L., Yang, T., & Qiu, C. (2020) · Medicine · doi:10.1097/md.0000000000020735 · Cited by 5
“Among them, LDL cholesterol is the most crucial risk factor for atherosclerotic cardiovascular disease (CVD), containing coronary artery diseases.([3,4]) In a Japanese observational study of type 2 diabetes mellitus,([5]) it was detected that serum triglycerides level was an independent and potent predictor of coronar…”
BackgroundSarel, Z., & Simanjuntak, K. (2020) · Jurnal Sehat Mandiri · doi:10.33761/jsm.v15i1.195 · Cited by 4
“Diabetes tipe 1 terjadi penurunan pembersihan VLDL dan peningkatan kerja Cholesterol Ester Transfer Protein(CETP).(9) Hiperkolesterolemia dan peningkatan kilomikron terjadi akibat beberapa perubahan diantaranya; resistensi insulin di enterosit dan jaringan lain,”
Improvement of Postprandial Lipid Metabolism After Ileal Transposition in Non-obese Diabetic Rats
Chen, W., Yin, H., Zhang, N., Liu, W., Qu, Q., Xiao, J., Gong, F., & He, X. (2021) · Obesity Surgery · doi:10.1007/s11695-020-05158-z · Cited by 4
Residual Risk Still Remains in Low-Density Lipoprotein
Hirano, T. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed187 · Cited by 4
Self-citationSuda, N., León-Martínez, D., Peter, P. R., Flannery, C. A., & Irani, R. A. (2025) · Case Reports in Endocrinology · doi:10.1155/crie/2644678 · Cited by 4
“Gly-cemic control was critical through both pregnancies as insulin resistance can disrupt lipid metabolism, leading to increased production and reduced clearance of TGs, and a decrease in LpL activity [25].”
Mkhize, B. C., Mosili, P., Ngubane, P. S., Sibiya, N. H., & Khathi, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125517 · Cited by 3
“Increased TGs and insulin resistance are known to promote hepatic cholesterol synthesis; hence, T2D increases FFA, TGs, and total cholesterol levels [69,70].”
Mthembu, S. X. H., Mazibuko-Mbeje, S. E., Ziqubu, K., Silvestri, S., Orlando, P., Nkambule, B. B., Muller, C. J. F., Tiano, L., & Dludla, P. V. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120474 · Cited by 6
Li, Z., & Xu, H. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05234-1 · Cited by 4
“Studies have shown that the ratio of TG to HDL-C has a significant impact on the severity of atherosclerosis and the prognosis of patients with diabetes and CVD [11].”
Niazi, A. A., Karajibani, M., Ghassami, K., Montazerifar, F., Iranneghad, M., & Bolouri, A. (2021) · Advances in Human Biology · doi:10.4103/aihb.aihb_26_21 · Cited by 3
Zhang, J., Mou, W., Chen, S., Wu, Z., Zhang, S.-H., Liu, P., Sun, H., Zhou, H., & Liu, Y. (2025) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2025.2506529 · Cited by 3
“Studies have shown that SR-BI-specific antibodies block the selective uptake of cholesterol and steroid synthesis from high-density lipoprotein cholesterol (HDL-C) in cultured cells (15, 16).”
InfluentialUnung, P. J., Bassey, I. E., Etukudo, M. H., Udoh, A. E., Alhassan, M. B., & Akpan, U. O. (2020) · PubMed Central · Cited by 4
Alterations of Obestatin, Cardiac Markers and Lipid Profile Levels in Type 2 Diabetes Mellitus
Balaky, H. M., & Kakey, I. S. (2021) · Iraqi Journal of Science · doi:10.24996/ijs.2021.62.6.6 · Cited by 4
“Thus, we assume that the low concentration of obestatin could be a predictor for T2DM patients, while the mechanisms are not quite understood.”
BackgroundInfluentialOakmoss Exhibits Antihyperglycemic Activity in Streptozotocin-Induced Diabetic Rats
Eddouks, M., Amssayef, A., & Bouadid, I. (2022) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x22666220316100022 · Cited by 3
Ivnitsky, J. J., Schäfer, T. V., Rejniuk, V. L., & Головко, А. И. (2022) · Journal of Applied Toxicology · doi:10.1002/jat.4312 · Cited by 5
“LDL cholesterol >3 mM and VLDL >1 mM are associated with an increased risk of atherosclerosis, Type 2 diabetes mellitus and cardiovascular disease (Hirano, 2018).”
BackgroundSun, M., Yan, S., Zhao, D., Wang, L., Feng, T., Yang, Y., Li, X., Hu, W., Yao, N., Cui, W., et al. (2022) · Nutrition & Metabolism · doi:10.1186/s12986-022-00665-5 · Cited by 3
“abnormalities caused by hyperglycemia [3, 4].”
Norouzi, Z., Zarezadeh, R., Mehdizadeh, A., Niafar, M., Germeyer, A., Fayyazpour, P., & Fayezi, S. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-04204-z · Cited by 5
“Lipid metabolism disorders, especially those involving changes in serum fatty acids, have been observed in patients with diabetes [18].”
BackgroundRole of LDL and Triglycerides in Hyperlipidemia in Diabetes Mellitus
Bethelli, S., & Oroszi, T. L. (2023) · Journal of Family Medicine and Disease Prevention · doi:10.23937/2469-5793/1510155 · Cited by 6
“As a result, adipose cells are continually breaking down and resynthesizing to provide energy, where triglycerides are stored [15,16].”
BackgroundANIMAL MODELS OF DIABETIC NEPHROPATHY
Azizah, D. U., Bahtiar, A., & Angelina, M. (2023) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2023.v16i8.48371 · Cited by 4
Lipid variability in patients with diabetes mellitus
Lee, J., & Lee, S. (2023) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2023.5.e18 · Cited by 7
“Instead, they develop hypertriglyceridemia as a result of impaired triglyceride clearance [3,8].”
BackgroundSong, R., Li, J., Xiong, Y., Huang, H., Liu, X., & Li, Q. (2024) · Medicine · doi:10.1097/md.0000000000038360 · Cited by 3
Al-Majidi, Z. A. Z., Lami, F., & Hakimi, S. (2024) · Journal of the Faculty of Medicine Baghdad · doi:10.32007/jfacmedbagdad.6622070 · Cited by 5
“(26,27) The disease characteristics investigated in this study were significantly associated with DM control.”
BackgroundPrapa, I., Yanni, A. E., Kompoura, V., Mitropoulou, G., Panas, P., Kostomitsopoulos, N. G., & Kourkoutas, Y. (2024) · Nutrients · doi:10.3390/nu16234221 · Cited by 4
Dang, A. K., Linh, L. T. T., Pham, N. M., Dũng, N. Q., Nguyen, H., Sơn, Đ. C., Nguyen, A. T., Le, H. T., Mamun, A. A., Phung, D. T., et al. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103171 · Cited by 7
Swarnakar, R., Sahu, D., Bahinipati, J., Pradhan, T., Meher, D., Sarangi, R., & Mahapatra, S. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1256_24 · Cited by 3
“[15] However, all T2DM patients do not present with dyslipidaemia which indicates the need for understanding factors responsible for these variations.”
Yudha, N. S. D., Arsana, P. M., & Rosandi, R. (2022) · Jurnal Penyakit Dalam Indonesia · doi:10.7454/jpdi.v8i4.592 · Cited by 5
Feng, L., Sun, Y., Liu, F., Wang, C., Zhang, C., Liu, J., & Jiang, L. (2022) · Current Research in Translational Medicine · doi:10.1016/j.retram.2022.103337 · Cited by 4
Kutoh, E., Wada, A., Kuto, A. N., Hayashi, J., & Kurihara, R. (2020) · Hospital Practice · doi:10.1080/21548331.2020.1732098 · Cited by 4
“TG levels had significantly decreased in group A and in the overall subjects (Tables 1 and 3), implicating that body weight reductions with canagliflozin have beneficial effects on TG, which is an important risk factor of cardiovascular disorders in addition to atherogenic LDL-C [24].”
BackgroundInfluentialChen, C., Wei, Y.-H., Huang, C.-C., Hung, S.-H., Wang, Z.-W., & Wong, R. (2021) · BioMed Research International · doi:10.1155/2021/5570827 · Cited by 4
“Hyperinsulinemia also increases liver production of very-low-density lipoprotein to increase serum TG, while simultaneously reducing HDLC production [5, 31].”
BackgroundSmall Dense LDL Tied to Diabetic Retinopathy-Similarity to Atherosclerosis
Hirano, T. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed174 · Cited by 3
Self-citation
Metadata
- Authors
- Hirano, T.
- Affiliations
- SHOWA Medical University (JP)
- Corresponding author
- Hirano, Tsutomu
- ORCID
- Hirano, Tsutomu
- Venue
- Journal of Atherosclerosis and Thrombosis
- Publisher
- Japan Atherosclerosis Society
- Published
- 2018-09-01
- Volume
- 25
- Issue
- 9
- Pages
- 771-782
- ISSN
- 1340-3478 (ISSN-L)
- 1880-3873
- PMC
- PMC6143775
- OpenAlex
- W2820707192
- Cited by
- 552
- References
- 102
- Citations by year
- 2026: 65 · 2025: 90 · 2024: 81 · 2023: 86 · 2022: 88 · 2021: 70 · 2020: 46 · 2019: 21 · 2018: 4
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Journal of Atherosclerosis and Thrombosis (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- diabetic dyslipidemia, type 2 diabetes, triglyceride-rich lipoproteins, VLDL, small dense LDL, HDL2, HDL3 cholesterol, insulin resistance, hyperinsulinemia, lipoprotein lipase, atherosclerotic cardiovascular disease, diabetic nephropathy, plasma lipid profile
- MeSH terms
- Pioglitazone, Animals, Cholesterol, Chylomicrons, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Fatty Acids, Nonesterified, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Lipoproteins, Cholesterol, HDL, Cholesterol, LDL, Lipoproteins, VLDL, Liver, Risk, Triglycerides, Cholesterol, VLDL, Dyslipidemias, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.